トレジェムバイオファーマ株式会社
京都 (Kyoto), JP · 2 known investors
Toregem Biopharma is a Kyoto University spin-off developing a tooth-regeneration drug based on a humanized anti-USAG-1 antibody that aims to regrow teeth with a single injection. It initially targets patients with congenital tooth agenesis (a rare genetic condition) and ultimately aims to treat tooth loss from decay or periodontal disease.
Founders & leadership
喜ほ
喜早 ほのか (Honoka Kihayashi)代表取締役社長 (Representative Director and President)
髙克
髙橋 克 (Katsu Takahashi)取締役CTO (Director and CTO)
髙宗
髙谷 宗男 (Muneo Takaya)取締役CBO (Director and CBO)
喜ほ
喜早 ほのかCo-founder & CEO (代表取締役社長)
髙克
髙橋 克Co-founder & CTO
髙宗
髙谷 宗男Co-founder & CBO
Investors · 2
Competitors · 1
by search overlapCompanies competing with トレジェムバイオファーマ株式会社 for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does トレジェムバイオファーマ株式会社 do?
- Toregem Biopharma is a Kyoto University spin-off developing a tooth-regeneration drug based on a humanized anti-USAG-1 antibody that aims to regrow teeth with a single injection. It initially targets patients with congenital tooth agenesis (a rare genetic condition) and ultimately aims to treat tooth loss from decay or periodontal disease.
- Who founded トレジェムバイオファーマ株式会社?
- トレジェムバイオファーマ株式会社 was founded by 喜早 ほのか (Honoka Kihayashi), 髙橋 克 (Katsu Takahashi), 髙谷 宗男 (Muneo Takaya), 喜早 ほのか, 髙橋 克, 髙谷 宗男.
- Who are トレジェムバイオファーマ株式会社's investors?
- トレジェムバイオファーマ株式会社's investors include Astellas Venture Management LLC, Kyoto University Innovation Capital.
- Where is トレジェムバイオファーマ株式会社 headquartered?
- トレジェムバイオファーマ株式会社 is headquartered in 京都 (Kyoto), JP.